P-10, r. 3.2 - Regulation respecting the initiation and modification of medication therapy, the administration of a medication and the prescription of tests by a pharmacist

Section 1 Disposition versions

2022-03-31

1. In the practice of the profession, a pharmacist may prescribe a medication listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12) for

(1)  smoking cessation;

(2)  hormonal contraception for an initial period of not more than 6 months;

(3)  emergency oral contraception;

(4)  prevention of nausea and vomiting;

(5)  taking charge of an emergency requiring the administration of a medication of the therapeutic sub-subclass of beta adrenergic agonists;

(6)  antibiotic prophylaxis in patients exposed to Lyme disease;

(7)  antibiotic prophylaxis in patients who are valve carriers;

(8)  prophylaxis in patients at risk of developing complications from influenza or coronavirus disease;

(9)  cytoprotective prophylaxis in patients at risk;

(10)  prophylaxis of acute mountain sickness, excluding the prescription of dexamethasone or sildenafil;

(11)  malaria prophylaxis;

(12)  prophylaxis after accidental exposure to HIV, to the extent that the pharmacist refers the patient to the professional authorized to ensure the patient’s clinical follow-up within 72 hours after the initiation of the medication therapy and enters the reasons justifying such decision on a form that the pharmacist gives to the patient;

(13)  perinatal vitamin supplementation;

(14)  vaccination;

(15)  allergic contact dermatitis requiring a weak or moderate strength topical corticosteroid therapy;

(16)  treatment of traveller’s diarrhea;

(17)  treatment of dyspepsia and gastroesophageal reflux for a maximum of 4 consecutive weeks or 6 cumulative weeks per 1-year period;

(18)  gonorrhea and chlamydia treatment of a patient covered by a program of the Ministère de la Santé et des Services sociaux for the accelerated treatment of partners; and

(19)  treatment of mild to moderate nausea and vomiting.

O.C. 1401-2020, s. 1; O.C. 622-2022, s. 1.

2021-01-25

1. In the practice of the profession, a pharmacist may prescribe a medication listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12) for

(1)  smoking cessation;

(2)  hormonal contraception for an initial period of not more than 6 months;

(3)  emergency oral contraception;

(4)  prevention of nausea and vomiting;

(5)  taking charge of an emergency requiring the administration of a medication of the therapeutic sub-subclass of beta adrenergic agonists;

(6)  antibiotic prophylaxis in patients exposed to Lyme disease;

(7)  antibiotic prophylaxis in patients who are valve carriers;

(8)  antiviral prophylaxis in patients at risk of developing complications from influenza;

(9)  cytoprotective prophylaxis in patients at risk;

(10)  prophylaxis of acute mountain sickness, excluding the prescription of dexamethasone or sildenafil;

(11)  malaria prophylaxis;

(12)  prophylaxis after accidental exposure to HIV, to the extent that the pharmacist refers the patient to the professional authorized to ensure the patient’s clinical follow-up within 72 hours after the initiation of the medication therapy and enters the reasons justifying such decision on a form that the pharmacist gives to the patient;

(13)  perinatal vitamin supplementation;

(14)  vaccination;

(15)  allergic contact dermatitis requiring a weak or moderate strength topical corticosteroid therapy;

(16)  treatment of traveller’s diarrhea;

(17)  treatment of dyspepsia and gastroesophageal reflux for a maximum of 4 consecutive weeks or 6 cumulative weeks per 1-year period;

(18)  gonorrhea and chlamydia treatment of a patient covered by a program of the Ministère de la Santé et des Services sociaux for the accelerated treatment of partners; and

(19)  treatment of mild to moderate nausea and vomiting.

O.C. 1401-2020, s. 1.

Not in force

In force: 2021-01-25

1. In the practice of the profession, a pharmacist may prescribe a medication listed in Schedule I of the Regulation respecting the terms and conditions for the sale of medications (chapter P-10, r. 12) for

(1)  smoking cessation;

(2)  hormonal contraception for an initial period of not more than 6 months;

(3)  emergency oral contraception;

(4)  prevention of nausea and vomiting;

(5)  taking charge of an emergency requiring the administration of a medication of the therapeutic sub-subclass of beta adrenergic agonists;

(6)  antibiotic prophylaxis in patients exposed to Lyme disease;

(7)  antibiotic prophylaxis in patients who are valve carriers;

(8)  antiviral prophylaxis in patients at risk of developing complications from influenza;

(9)  cytoprotective prophylaxis in patients at risk;

(10)  prophylaxis of acute mountain sickness, excluding the prescription of dexamethasone or sildenafil;

(11)  malaria prophylaxis;

(12)  prophylaxis after accidental exposure to HIV, to the extent that the pharmacist refers the patient to the professional authorized to ensure the patient’s clinical follow-up within 72 hours after the initiation of the medication therapy and enters the reasons justifying such decision on a form that the pharmacist gives to the patient;

(13)  perinatal vitamin supplementation;

(14)  vaccination;

(15)  allergic contact dermatitis requiring a weak or moderate strength topical corticosteroid therapy;

(16)  treatment of traveller’s diarrhea;

(17)  treatment of dyspepsia and gastroesophageal reflux for a maximum of 4 consecutive weeks or 6 cumulative weeks per 1-year period;

(18)  gonorrhea and chlamydia treatment of a patient covered by a program of the Ministère de la Santé et des Services sociaux for the accelerated treatment of partners; and

(19)  treatment of mild to moderate nausea and vomiting.

O.C. 1401-2020, s. 1.